This is a Validated Antibody Database (VAD) review about mouse Havcr2, based on 56 published articles (read how Labome selects the articles), using Havcr2 antibody in all methods. It is aimed to help Labome visitors find the most suited Havcr2 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
Havcr2 synonym: TIM-3; Tim3; Timd3

BioLegend
rat monoclonal (B8.2C12)
  • flow cytometry; mouse; 1:50; fig 4a
BioLegend Havcr2 antibody (Biolegend, 134004) was used in flow cytometry on mouse samples at 1:50 (fig 4a). Nat Commun (2022) ncbi
rat monoclonal (RMT3-23)
  • flow cytometry; mouse; loading ...; fig 2a
BioLegend Havcr2 antibody (BioLegend, 119718) was used in flow cytometry on mouse samples (fig 2a). Sci Adv (2022) ncbi
rat monoclonal (B8.2C12)
  • flow cytometry; mouse; 1:200; fig 4d, s5d
BioLegend Havcr2 antibody (BioLegend, 134008) was used in flow cytometry on mouse samples at 1:200 (fig 4d, s5d). Cell Rep (2022) ncbi
rat monoclonal (B8.2C12)
  • flow cytometry; mouse; fig s6b
BioLegend Havcr2 antibody (Biolegend, B8.2C12) was used in flow cytometry on mouse samples (fig s6b). Nat Commun (2022) ncbi
rat monoclonal (RMT3-23)
  • flow cytometry; mouse; 1:50; loading ...; fig 6j, s8
BioLegend Havcr2 antibody (Biolegend, 119715) was used in flow cytometry on mouse samples at 1:50 (fig 6j, s8). Nat Commun (2022) ncbi
rat monoclonal (RMT3-23)
  • flow cytometry; mouse
BioLegend Havcr2 antibody (Biolegend, 119721) was used in flow cytometry on mouse samples . Theranostics (2021) ncbi
rat monoclonal (B8.2C12)
  • flow cytometry; mouse; 1:600; fig s2e
BioLegend Havcr2 antibody (BioLegend, B8.2C12) was used in flow cytometry on mouse samples at 1:600 (fig s2e). Sci Adv (2021) ncbi
rat monoclonal (RMT3-23)
  • flow cytometry; mouse; loading ...
BioLegend Havcr2 antibody (Biolegend, RMT3-23) was used in flow cytometry on mouse samples . Int J Mol Sci (2021) ncbi
rat monoclonal (B8.2C12)
  • flow cytometry; mouse; loading ...; fig 5a
BioLegend Havcr2 antibody (Biolegend, 134014) was used in flow cytometry on mouse samples (fig 5a). J Immunother Cancer (2021) ncbi
rat monoclonal (RMT3-23)
  • flow cytometry; mouse; loading ...; fig s2d
BioLegend Havcr2 antibody (Biolegend, 119721) was used in flow cytometry on mouse samples (fig s2d). Cell (2021) ncbi
rat monoclonal (B8.2C12)
  • flow cytometry; mouse; loading ...; fig s2d
BioLegend Havcr2 antibody (Biolegend, 134014) was used in flow cytometry on mouse samples (fig s2d). Cell (2021) ncbi
rat monoclonal (B8.2C12)
  • flow cytometry; mouse; fig s2c
BioLegend Havcr2 antibody (Biolegend, B8.2C12) was used in flow cytometry on mouse samples (fig s2c). J Immunother Cancer (2021) ncbi
rat monoclonal (RMT3-23)
  • flow cytometry; mouse; 1:100; fig 2g
BioLegend Havcr2 antibody (BioLegend, RMT3-23) was used in flow cytometry on mouse samples at 1:100 (fig 2g). Nat Commun (2021) ncbi
rat monoclonal (B8.2C12)
  • flow cytometry; mouse; 1:250; fig 7a
BioLegend Havcr2 antibody (BioLegend, 134006) was used in flow cytometry on mouse samples at 1:250 (fig 7a). Cancer Res (2021) ncbi
rat monoclonal (RMT3-23)
BioLegend Havcr2 antibody (BioLegend, RMT3-23) was used . Nature (2020) ncbi
rat monoclonal (RMT3-23)
  • flow cytometry; mouse; loading ...; fig 6e
BioLegend Havcr2 antibody (Biolegend, 119706) was used in flow cytometry on mouse samples (fig 6e). elife (2020) ncbi
rat monoclonal (B8.2C12)
  • flow cytometry; mouse; loading ...; fig 6s1
BioLegend Havcr2 antibody (Biolegend, B8.2C12) was used in flow cytometry on mouse samples (fig 6s1). elife (2020) ncbi
rat monoclonal (RMT3-23)
  • flow cytometry; mouse; loading ...; fig 4c
BioLegend Havcr2 antibody (BioLegend, 119721) was used in flow cytometry on mouse samples (fig 4c). Immunity (2019) ncbi
rat monoclonal (B8.2C12)
  • flow cytometry; mouse; loading ...; fig 5f
BioLegend Havcr2 antibody (Biolegend, 134003) was used in flow cytometry on mouse samples (fig 5f). Cell (2019) ncbi
rat monoclonal (RMT3-23)
  • flow cytometry; mouse; 1:100; fig 4a
BioLegend Havcr2 antibody (Biolegend, 119705) was used in flow cytometry on mouse samples at 1:100 (fig 4a). Nat Commun (2019) ncbi
rat monoclonal (RMT3-23)
  • flow cytometry; mouse; loading ...; fig s3h
BioLegend Havcr2 antibody (Biolegend, RMT3-23) was used in flow cytometry on mouse samples (fig s3h). JCI Insight (2019) ncbi
rat monoclonal (RMT3-23)
  • flow cytometry; mouse; loading ...; fig 2d
BioLegend Havcr2 antibody (BioLegend, RMT3-23) was used in flow cytometry on mouse samples (fig 2d). Nature (2019) ncbi
rat monoclonal (RMT3-23)
  • flow cytometry; mouse; 1:100; loading ...; fig s2b
BioLegend Havcr2 antibody (Biolegend, 119723) was used in flow cytometry on mouse samples at 1:100 (fig s2b). Nat Commun (2019) ncbi
rat monoclonal (RMT3-23)
  • flow cytometry; mouse; loading ...; fig s6f
BioLegend Havcr2 antibody (Biolegend, 119718) was used in flow cytometry on mouse samples (fig s6f). Cell (2019) ncbi
rat monoclonal (RMT3-23)
  • flow cytometry; mouse; loading ...; fig 2d
BioLegend Havcr2 antibody (Biolegend, RMT3-23) was used in flow cytometry on mouse samples (fig 2d). Science (2019) ncbi
rat monoclonal (RMT3-23)
  • flow cytometry; mouse; loading ...; fig 2e
BioLegend Havcr2 antibody (Biolegend, RMT3-23) was used in flow cytometry on mouse samples (fig 2e). Front Immunol (2018) ncbi
rat monoclonal (RMT3-23)
  • flow cytometry; mouse; loading ...; fig s2b, s2k
BioLegend Havcr2 antibody (BioLegend, RMT3-23) was used in flow cytometry on mouse samples (fig s2b, s2k). Cell Rep (2018) ncbi
rat monoclonal (B8.2C12)
  • flow cytometry; mouse; loading ...; fig 1d
BioLegend Havcr2 antibody (Biolegend, 134004) was used in flow cytometry on mouse samples (fig 1d). elife (2018) ncbi
rat monoclonal (RMT3-23)
  • flow cytometry; mouse; loading ...; fig s12a
BioLegend Havcr2 antibody (BioLegend, RMT3-23) was used in flow cytometry on mouse samples (fig s12a). J Clin Invest (2018) ncbi
rat monoclonal (B8.2C12)
  • flow cytometry; mouse; loading ...; fig e4d
BioLegend Havcr2 antibody (Biolegend, B8.2c12) was used in flow cytometry on mouse samples (fig e4d). Nature (2018) ncbi
rat monoclonal (RMT3-23)
  • flow cytometry; mouse; fig 4j
BioLegend Havcr2 antibody (BioLegend, 119716) was used in flow cytometry on mouse samples (fig 4j). Cell (2018) ncbi
rat monoclonal (B8.2C12)
  • flow cytometry; mouse; fig 3e
BioLegend Havcr2 antibody (Biolegend, B8.2C12) was used in flow cytometry on mouse samples (fig 3e). JCI Insight (2017) ncbi
rat monoclonal (RMT3-23)
  • flow cytometry; mouse; loading ...; fig 4h
BioLegend Havcr2 antibody (Biolegend, RMT3-23) was used in flow cytometry on mouse samples (fig 4h). Nature (2017) ncbi
rat monoclonal (RMT3-23)
  • flow cytometry; mouse; loading ...; fig s12a
In order to evaluate mouse models of hepacivirus infection, BioLegend Havcr2 antibody (Biolegend, RMT3-23) was used in flow cytometry on mouse samples (fig s12a). Science (2017) ncbi
rat monoclonal (RMT3-23)
  • flow cytometry; mouse; loading ...; fig s3f
In order to investigate the use of red blood cells expressing disease-associated autoantigenas a means of inducing antigen-specific tolerance, BioLegend Havcr2 antibody (BioLegend, 119706) was used in flow cytometry on mouse samples (fig s3f). Proc Natl Acad Sci U S A (2017) ncbi
rat monoclonal (B8.2C12)
  • flow cytometry; mouse; 1:800; loading ...; tbl s2
In order to identify and characterize follicular cytotoxic T cells, BioLegend Havcr2 antibody (Biolegend, B8.2C12) was used in flow cytometry on mouse samples at 1:800 (tbl s2). Nat Immunol (2016) ncbi
rat monoclonal (B8.2C12)
  • flow cytometry; mouse; loading ...; fig 2b
In order to test if blocking several checkpoint receptors boosts anti-tumor immunity in a low-dose, lymphodepleting whole body radiation model, BioLegend Havcr2 antibody (Biolegend, B8.2C12) was used in flow cytometry on mouse samples (fig 2b). J Immunother Cancer (2015) ncbi
Invitrogen
rat monoclonal (RMT3-23)
  • flow cytometry; mouse; 1:100; loading ...; fig 7d
Invitrogen Havcr2 antibody (eBioscience, 11-5870-82) was used in flow cytometry on mouse samples at 1:100 (fig 7d). Nat Commun (2022) ncbi
rat monoclonal (8B.2C12)
  • flow cytometry; mouse; 1:200; loading ...
Invitrogen Havcr2 antibody (eBioscience, 8B.2C12) was used in flow cytometry on mouse samples at 1:200. Nat Commun (2021) ncbi
rat monoclonal (RMT3-23)
  • flow cytometry; mouse; 1:50; loading ...; fig s2a
Invitrogen Havcr2 antibody (Thermo Fisher Scientific, RMT3-23) was used in flow cytometry on mouse samples at 1:50 (fig s2a). Nat Immunol (2021) ncbi
rat monoclonal (RMT3-23)
  • flow cytometry; mouse; 1:400; loading ...; fig ex4b
Invitrogen Havcr2 antibody (ThermoFisher, RMT3-23) was used in flow cytometry on mouse samples at 1:400 (fig ex4b). Nat Med (2019) ncbi
rat monoclonal (RMT3-23)
  • flow cytometry; mouse; loading ...; fig ex2b
Invitrogen Havcr2 antibody (eBioscience, 12-5870-81) was used in flow cytometry on mouse samples (fig ex2b). Nature (2019) ncbi
rat monoclonal (RMT3-23)
  • flow cytometry; mouse; 1:100; loading ...; fig 3b
Invitrogen Havcr2 antibody (eBioscience, RMT3-23) was used in flow cytometry on mouse samples at 1:100 (fig 3b). Infect Immun (2018) ncbi
rat monoclonal (8B.2C12)
  • flow cytometry; mouse; 1:300; loading ...; fig 6f
In order to test if oncolytic poxvirus treatment improves anti-PD-L1 immunotherapy, Invitrogen Havcr2 antibody (eBioscience, 13-5871-82) was used in flow cytometry on mouse samples at 1:300 (fig 6f). Nat Commun (2017) ncbi
rat monoclonal (8B.2C12)
  • flow cytometry; mouse; loading ...; fig 1,3
In order to elucidate the interaction between tumor-associated and -infiltrating lymphocytes in ovarian cancer, Invitrogen Havcr2 antibody (eBioscience, 17-5871-82) was used in flow cytometry on mouse samples (fig 1,3). Oncoimmunology (2017) ncbi
rat monoclonal (RMT3-23)
  • flow cytometry; mouse; loading ...; fig 2e
Invitrogen Havcr2 antibody (eBioscience, RMT3-23) was used in flow cytometry on mouse samples (fig 2e). Blood (2017) ncbi
rat monoclonal (RMT3-23)
  • flow cytometry; mouse; loading ...; fig 5
In order to report the effects of PD-L1 modulation of T cell function in graft-versus-host disease, Invitrogen Havcr2 antibody (eBioscience, RMT3-23) was used in flow cytometry on mouse samples (fig 5). J Clin Invest (2016) ncbi
rat monoclonal (RMT3-23)
  • blocking or activating experiments; mouse; fig 3
  • flow cytometry; mouse; 2 ug/ml; fig 1
Invitrogen Havcr2 antibody (eBioscience, RMT-3-23) was used in blocking or activating experiments on mouse samples (fig 3) and in flow cytometry on mouse samples at 2 ug/ml (fig 1). Nat Commun (2015) ncbi
rat monoclonal (RMT3-23)
  • flow cytometry; mouse; fig s1
In order to test if blocking several checkpoint receptors boosts anti-tumor immunity in a low-dose, lymphodepleting whole body radiation model, Invitrogen Havcr2 antibody (eBioscience, RMT3-23) was used in flow cytometry on mouse samples (fig s1). J Immunother Cancer (2015) ncbi
rat monoclonal (RMT3-23)
  • flow cytometry; mouse; fig 2
Invitrogen Havcr2 antibody (eBioscience, RMT3-23) was used in flow cytometry on mouse samples (fig 2). PLoS Pathog (2015) ncbi
rat monoclonal (8B.2C12)
  • flow cytometry; mouse; loading ...; fig 1a
In order to study the function of Tim-3 in microglia., Invitrogen Havcr2 antibody (eBioscience, 12-5871) was used in flow cytometry on mouse samples (fig 1a). Cell Immunol (2015) ncbi
rat monoclonal (8B.2C12)
  • flow cytometry; mouse; 1:200
Invitrogen Havcr2 antibody (eBioscience, 8B.2C12) was used in flow cytometry on mouse samples at 1:200. Nat Commun (2014) ncbi
rat monoclonal (RMT3-23)
  • flow cytometry; mouse; fig 3
In order to characterize and compare T helper 1 and 17 cells, Invitrogen Havcr2 antibody (eBiosciences, RMT3- 23) was used in flow cytometry on mouse samples (fig 3). J Leukoc Biol (2007) ncbi
Abcam
domestic rabbit monoclonal (EPR22241)
  • immunohistochemistry; human; 1:500; loading ...; fig 5a
Abcam Havcr2 antibody (Abcam, ab241332) was used in immunohistochemistry on human samples at 1:500 (fig 5a). Adv Sci (Weinh) (2021) ncbi
domestic rabbit polyclonal
  • western blot; mouse; loading ...; fig 4h
Abcam Havcr2 antibody (Abcam, ab185703) was used in western blot on mouse samples (fig 4h). elife (2018) ncbi
Bio X Cell
rat monoclonal (RMT3-23)
  • blocking or activating experiments; mouse; loading ...; fig 5c
Bio X Cell Havcr2 antibody (BioXcell, BE0115) was used in blocking or activating experiments on mouse samples (fig 5c). Oncogene (2018) ncbi
rat monoclonal (RMT3-23)
  • blocking or activating experiments; mouse; loading ...; fig 2
Bio X Cell Havcr2 antibody (BioXCell, RMT3-23) was used in blocking or activating experiments on mouse samples (fig 2). PLoS ONE (2015) ncbi
rat monoclonal (RMT3-23)
  • blocking or activating experiments; mouse; loading ...; fig 3
  • flow cytometry; mouse; loading ...; fig 2a
Bio X Cell Havcr2 antibody (Bio-X-cell, RMT3-23) was used in blocking or activating experiments on mouse samples (fig 3) and in flow cytometry on mouse samples (fig 2a). Mol Immunol (2014) ncbi
R&D Systems
domestic goat polyclonal
R&D Systems Havcr2 antibody (R&D Systems, AF1529) was used . Nat Commun (2015) ncbi
Miltenyi Biotec
rat monoclonal (RMT3-23)
  • flow cytometry; mouse; loading ...; fig 3
In order to investigate the regulated egress of T-cell subsets from tumors, Miltenyi Biotec Havcr2 antibody (Miltenyi Biotech, RMT3-23) was used in flow cytometry on mouse samples (fig 3). Proc Natl Acad Sci U S A (2017) ncbi
Articles Reviewed
  1. Ravindranathan S, Passang T, Li J, Wang S, Dhamsania R, Ware M, et al. Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma. Nat Commun. 2022;13:6418 pubmed publisher
  2. Que W, Ma K, Hu X, Guo W, Li X. Combinations of anti-GITR antibody and CD28 superagonist induce permanent allograft acceptance by generating type 1 regulatory T cells. Sci Adv. 2022;8:eabo4413 pubmed publisher
  3. Xie F, Zhou X, Su P, Li H, Tu Y, Du J, et al. Breast cancer cell-derived extracellular vesicles promote CD8+ T cell exhaustion via TGF-β type II receptor signaling. Nat Commun. 2022;13:4461 pubmed publisher
  4. Taniguchi H, Caeser R, Chavan S, Zhan Y, Chow A, Manoj P, et al. WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC. Cell Rep. 2022;39:110814 pubmed publisher
  5. Piao W, Li L, Saxena V, Iyyathurai J, Lakhan R, Zhang Y, et al. PD-L1 signaling selectively regulates T cell lymphatic transendothelial migration. Nat Commun. 2022;13:2176 pubmed publisher
  6. Xiong W, Gao X, Zhang T, Jiang B, Hu M, Bu X, et al. USP8 inhibition reshapes an inflamed tumor microenvironment that potentiates the immunotherapy. Nat Commun. 2022;13:1700 pubmed publisher
  7. Jiang Y, Yuan Y, Chen M, Li S, Bai J, Zhang Y, et al. PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression. Theranostics. 2021;11:9162-9176 pubmed publisher
  8. Rizvi Z, Dalal R, Sadhu S, Kumar Y, Kumar S, Gupta S, et al. High-salt diet mediates interplay between NK cells and gut microbiota to induce potent tumor immunity. Sci Adv. 2021;7:eabg5016 pubmed publisher
  9. Neumann S, Campbell K, Woodall M, Evans M, Clarkson A, Young S. Obesity Has a Systemic Effect on Immune Cells in Naïve and Cancer-Bearing Mice. Int J Mol Sci. 2021;22: pubmed publisher
  10. Lauret Marie Joseph E, Kirilovsky A, Lecoester B, El Sissy C, Boullerot L, Rangan L, et al. Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy. J Immunother Cancer. 2021;9: pubmed publisher
  11. Amoozgar Z, Kloepper J, Ren J, Tay R, Kazer S, Kiner E, et al. Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas. Nat Commun. 2021;12:2582 pubmed publisher
  12. Gangoso E, Southgate B, Bradley L, Rus S, Gálvez Cancino F, McGivern N, et al. Glioblastomas acquire myeloid-affiliated transcriptional programs via epigenetic immunoediting to elicit immune evasion. Cell. 2021;184:2454-2470.e26 pubmed publisher
  13. Choi Y, Kim Y, Oh S, Suh K, Kim Y, Lee G, et al. Senescent Tumor Cells Build a Cytokine Shield in Colorectal Cancer. Adv Sci (Weinh). 2021;8:2002497 pubmed publisher
  14. Can xe8 S, Van Snick J, Uyttenhove C, Pilotte L, van den Eynde B. TGFβ1 neutralization displays therapeutic efficacy through both an immunomodulatory and a non-immune tumor-intrinsic mechanism. J Immunother Cancer. 2021;9: pubmed publisher
  15. Page N, Lemeille S, Vincenti I, Klimek B, Mariotte A, Wagner I, et al. Persistence of self-reactive CD8+ T cells in the CNS requires TOX-dependent chromatin remodeling. Nat Commun. 2021;12:1009 pubmed publisher
  16. Yao C, Lou G, Sun H, Zhu Z, Sun Y, Chen Z, et al. BACH2 enforces the transcriptional and epigenetic programs of stem-like CD8+ T cells. Nat Immunol. 2021;22:370-380 pubmed publisher
  17. Kharkwal S, Johndrow C, Veerapen N, Kharkwal H, Saavedra Avila N, Carreño L, et al. Serial Stimulation of Invariant Natural Killer T Cells with Covalently Stabilized Bispecific T-cell Engagers Generates Antitumor Immunity While Avoiding Anergy. Cancer Res. 2021;81:1788-1801 pubmed publisher
  18. Yamamoto K, Venida A, Yano J, Biancur D, Kakiuchi M, Gupta S, et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature. 2020;581:100-105 pubmed publisher
  19. Hajaj E, Eisenberg G, Klein S, Frankenburg S, Merims S, Ben David I, et al. SLAMF6​ deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint. elife. 2020;9: pubmed publisher
  20. Canel M, Taggart D, Sims A, Lonergan D, Waizenegger I, Serrels A. T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity. elife. 2020;9: pubmed publisher
  21. Chen Z, Ji Z, Ngiow S, Manne S, Cai Z, Huang A, et al. TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 T Cell-Fate Decision. Immunity. 2019;51:840-855.e5 pubmed publisher
  22. Dong M, Wang G, Chow R, Ye L, Zhu L, Dai X, et al. Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells. Cell. 2019;178:1189-1204.e23 pubmed publisher
  23. Leclerc M, Voilin E, Gros G, Corgnac S, de Montpreville V, Validire P, et al. Regulation of antitumour CD8 T-cell immunity and checkpoint blockade immunotherapy by Neuropilin-1. Nat Commun. 2019;10:3345 pubmed publisher
  24. Wirsching H, Zhang H, Szulzewsky F, Arora S, Grandi P, Cimino P, et al. Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma. JCI Insight. 2019;4: pubmed publisher
  25. Khan O, Giles J, McDonald S, Manne S, Ngiow S, Patel K, et al. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature. 2019;: pubmed publisher
  26. LaFleur M, Nguyen T, Coxe M, Yates K, Trombley J, Weiss S, et al. A CRISPR-Cas9 delivery system for in vivo screening of genes in the immune system. Nat Commun. 2019;10:1668 pubmed publisher
  27. Hammerich L, Marron T, Upadhyay R, Svensson Arvelund J, Dhainaut M, Hussein S, et al. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat Med. 2019;25:814-824 pubmed publisher
  28. Poggio M, Hu T, Pai C, Chu B, BELAIR C, Chang A, et al. Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory. Cell. 2019;177:414-427.e13 pubmed publisher
  29. Chen J, López Moyado I, Seo H, Lio C, Hempleman L, Sekiya T, et al. NR4A transcription factors limit CAR T cell function in solid tumours. Nature. 2019;567:530-534 pubmed publisher
  30. Cox M, Duncan G, Lin G, Steinberg B, Yu L, Brenner D, et al. Choline acetyltransferase-expressing T cells are required to control chronic viral infection. Science. 2019;363:639-644 pubmed publisher
  31. Li J, He Y, Hao J, Ni L, Dong C. High Levels of Eomes Promote Exhaustion of Anti-tumor CD8+ T Cells. Front Immunol. 2018;9:2981 pubmed publisher
  32. Ding L, Kim H, Wang Q, Kearns M, Jiang T, Ohlson C, et al. PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer. Cell Rep. 2018;25:2972-2980.e5 pubmed publisher
  33. Zhu H, Zhang L, Wu Y, Dong B, Guo W, Wang M, et al. T-ALL leukemia stem cell 'stemness' is epigenetically controlled by the master regulator SPI1. elife. 2018;7: pubmed publisher
  34. Splitt S, Souza S, Valentine K, Castellanos B, Curd A, Hoyer K, et al. PD-L1, TIM-3, and CTLA-4 Blockade Fails To Promote Resistance to Secondary Infection with Virulent Strains of Toxoplasma gondii. Infect Immun. 2018;86: pubmed publisher
  35. Vendetti F, Karukonda P, Clump D, Teo T, Lalonde R, Nugent K, et al. ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation. J Clin Invest. 2018;128:3926-3940 pubmed publisher
  36. Du X, Wen J, Wang Y, Karmaus P, Khatamian A, Tan H, et al. Hippo/Mst signalling couples metabolic state and immune function of CD8α+ dendritic cells. Nature. 2018;558:141-145 pubmed publisher
  37. Zhang H, Song Y, Yang H, Liu Z, Gao L, Liang X, et al. Tumor cell-intrinsic Tim-3 promotes liver cancer via NF-κB/IL-6/STAT3 axis. Oncogene. 2018;37:2456-2468 pubmed publisher
  38. Böttcher J, Bonavita E, Chakravarty P, Blees H, Cabeza Cabrerizo M, Sammicheli S, et al. NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control. Cell. 2018;172:1022-1037.e14 pubmed publisher
  39. Pedros C, Canonigo Balancio A, Kong K, Altman A. Requirement of Treg-intrinsic CTLA4/PKCη signaling pathway for suppressing tumor immunity. JCI Insight. 2017;2: pubmed publisher
  40. Goel S, Decristo M, Watt A, BrinJones H, Sceneay J, Li B, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017;548:471-475 pubmed publisher
  41. Billerbeck E, Wolfisberg R, Fahnøe U, Xiao J, Quirk C, Luna J, et al. Mouse models of acute and chronic hepacivirus infection. Science. 2017;357:204-208 pubmed publisher
  42. Torcellan T, Hampton H, Bailey J, Tomura M, Brink R, Chtanova T. In vivo photolabeling of tumor-infiltrating cells reveals highly regulated egress of T-cell subsets from tumors. Proc Natl Acad Sci U S A. 2017;114:5677-5682 pubmed publisher
  43. Liu Z, Ravindranathan R, Kalinski P, Guo Z, Bartlett D. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat Commun. 2017;8:14754 pubmed publisher
  44. Pishesha N, Bilate A, Wibowo M, Huang N, Li Z, Deshycka R, et al. Engineered erythrocytes covalently linked to antigenic peptides can protect against autoimmune disease. Proc Natl Acad Sci U S A. 2017;114:3157-3162 pubmed publisher
  45. Huang R, Francois A, McGray A, Miliotto A, Odunsi K. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology. 2017;6:e1249561 pubmed publisher
  46. Asano T, Meguri Y, Yoshioka T, Kishi Y, Iwamoto M, Nakamura M, et al. PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. Blood. 2017;129:2186-2197 pubmed publisher
  47. Leong Y, Chen Y, Ong H, Wu D, Man K, Deléage C, et al. CXCR5(+) follicular cytotoxic T cells control viral infection in B cell follicles. Nat Immunol. 2016;17:1187-96 pubmed publisher
  48. Saha A, O Connor R, Thangavelu G, Lovitch S, Dandamudi D, Wilson C, et al. Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. J Clin Invest. 2016;126:2642-60 pubmed publisher
  49. Tripathi S, Chabtini L, Dakle P, Smith B, Akiba H, Yagita H, et al. Effect of TIM-3 Blockade on the Immunophenotype and Cytokine Profile of Murine Uterine NK Cells. PLoS ONE. 2015;10:e0123439 pubmed publisher
  50. Koh H, Chang C, Jeon S, Yoon H, Ahn Y, Kim H, et al. The HIF-1/glial TIM-3 axis controls inflammation-associated brain damage under hypoxia. Nat Commun. 2015;6:6340 pubmed publisher
  51. Jing W, Gershan J, Weber J, Tlomak D, McOlash L, Sabatos Peyton C, et al. Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma. J Immunother Cancer. 2015;3:2 pubmed publisher
  52. Clouthier D, Zhou A, Wortzman M, Luft O, Levy G, Watts T. GITR intrinsically sustains early type 1 and late follicular helper CD4 T cell accumulation to control a chronic viral infection. PLoS Pathog. 2015;11:e1004517 pubmed publisher
  53. Wang H, Zhu X, Qin L, Qian H, Wang Y. Microglia activity modulated by T cell Ig and mucin domain protein 3 (Tim-3). Cell Immunol. 2015;293:49-58 pubmed publisher
  54. Burton B, Britton G, Fang H, Verhagen J, Smithers B, Sabatos Peyton C, et al. Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapy. Nat Commun. 2014;5:4741 pubmed publisher
  55. Ju Y, Shang X, Liu Z, Zhang J, Li Y, Shen Y, et al. The Tim-3/galectin-9 pathway involves in the homeostasis of hepatic Tregs in a mouse model of concanavalin A-induced hepatitis. Mol Immunol. 2014;58:85-91 pubmed publisher
  56. Nakae S, Iwakura Y, Suto H, Galli S. Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17. J Leukoc Biol. 2007;81:1258-68 pubmed